vimarsana.com

Page 3 - அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Half of Kids with Inflammatory Syndrome After COVID-19 Have Neurologic Symptoms

Share this article Share this article MINNEAPOLIS, April 17, 2021 /PRNewswire/  Half of the children who developed the serious condition associated with COVID-19 called multisystem inflammatory syndrome in children (MIS-C) had neurologic symptoms or signs when they entered the hospital, according to preliminary research that will be presented at the American Academy of Neurology s 73rd Annual Meeting being held virtually April 17 to 22, 2021. Those symptoms included headaches, encephalopathy and hallucinations. With this new inflammatory syndrome that develops after children are infected with the coronavirus, we are still learning how the syndrome affects children and what we need to watch out for, said study author Omar Abdel-Mannan, MD, of University College London in the United Kingdom and a member of the American Academy of Neurology. We found that many children experienced neurologic symptoms involving both the central and peripheral nervous systems.

Autobahn Therapeutics : Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

Message : Required fields First Data Presented Showcasing Autobahn’s Novel FAAH-Mediated Prodrug Approach for Selective Delivery of Thyromimetics to the Brain Treatment with ABX-002 Leads to Reductions in VLCFA in Brain Tissue and Plasma in AMN Mouse Model Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of adrenomyeloneuropathy (AMN), a progressive and debilitating rare disease. The data will be highlighted in a poster presentation at the American Academy of Neurology Annual Meeting, which is being held virtually from April 17-22, 2021. Posters will be made available at the start of the conference and remain viewable online through the virtual forum for 30 days after the meeting.

Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

Share: First Data Presented Showcasing Autobahn s Novel FAAH-Mediated Prodrug Approach for Selective Delivery of Thyromimetics to the Brain Treatment with ABX-002 Leads to Reductions in VLCFA in Brain Tissue and Plasma in AMN Mouse Model Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of adrenomyeloneuropathy (AMN), a progressive and debilitating rare disease. The data will be highlighted in a poster presentation at the American Academy of Neurology Annual Meeting, which is being held virtually from April 17-22, 2021. Posters will be made available at the start of the conference and remain viewable online through the virtual forum for 30 days after the meeting.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.